Ono gets rights to SINE compounds from Karyopharm

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights to develop and commercialize selinexor (KPT-330) and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries to treat cancer.

Karyopharm will receive ¥2.5 billion ($22 million) up front and is eligible for up to ¥19.2 billion ($170 million) in milestones, plus low double-digit royalties. Ono is responsible for development and commercialization of the compounds in the territory. The pharma declined to provide regulatory timelines...